Please login to the form below

Not currently logged in
Email:
Password:

anxiety

This page shows the latest anxiety news and features for those working in and with pharma, biotech and healthcare.

Sage’s postpartum depression treatment Zulresso gains US approval

Sage’s postpartum depression treatment Zulresso gains US approval

Unlike conventional antidepressants, which can take weeks to kick in, the single infusion starts working within 2-3 days of dosing and can lift women quickly out of the sadness, anxiety,

Latest news

More from news
Approximately 1 fully matching, plus 142 partially matching documents found.

Latest Intelligence

  • Changing healthcare communications Changing healthcare communications

    Replacing anxiety with confidence, mediocrity with purpose. By David Hunt and Lou Shipley. ... But only if we replace anxiety with confidence, mediocrity with purpose, and attract the brightest, smartest and most creative minds to join our cause.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    There were also significant improvements for AbbVie’s drug over Humira on quality of life measures and over Stelara on anxiety and depression, and risankizumab did better than both comparator drugs

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Galbraith is concerned about the rise in reported anxiety and mental health problems in young people, with young women most vulnerable.

  • The Patient Safety Challenge The Patient Safety Challenge

    There were anxieties about how reporting could affect their reputations and career prospects.

  • Finding the patient voice Finding the patient voice

    This data provided the big picture about what motivates people to join clinical trials, their anxieties and their experiences. ... we should communicate with them, depending on their needs and anxieties.

More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest appointments

  • Dr Niall Murphy and Pierre Schwich join Pharnext Dr Niall Murphy and Pierre Schwich join Pharnext

    Prior to this, Dr Murphy served as a unit leader for a team of scientists collaborating on research in the areas of addition biology, Alzheimer's disease, anxiety, depression and neurotoxicity

  • Turing names Eliseo Salinas as head of R&D Turing names Eliseo Salinas as head of R&D

    Salinas has played a leading role in numerous programmes for a range of diseases and disorders, with specific focus on central nervous systems (CNS) condition such as depression and anxiety, schizophrenia,

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 20 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics